Shao-lee Lin

Dr. Shao-lee Lin is currently the Executive Vice President, Head of Research and Development, and Chief Scientific Officer at Horizon Pharma Plc. Prior to this, they served as the Corporate Officer for Leading Therapeutic Areas, Development Excellence, and International Development at AbbVie from March 2015 to December 2017. Before that, Dr. Lin was the Vice President of Inflammation and Respiratory Therapeutics at Gilead Sciences from August 2012 to February 2015.

Dr. Lin began their career as a faculty member in the Department of Chemistry at Lake Forest College. Shao-lee then spent time as a medicinal chemist at Principia Biopharma and ACELYRIN, INC. before joining Third Harmonic Bio as the company's Executive Vice President and Chief Scientific Officer.

Under Dr. Lin's leadership, the research and development team at Horizon Pharma Plc has made significant strides in developing new medicines for patients with rare diseases. These achievements have resulted in a tripling of the company value within two years and have established Horizon Pharma Plc as a leading biopharmaceutical company.

Shao-lee Lin has an MD and a PhD in Immunology from The Johns Hopkins University School of Medicine. Shao-lee also has a degree in Chemical Engineering and Biochemistry from Rice University.

Some of their coworkers include Geoffrey M. Curtis - Executive Vice President, Corporate Affairs and Chief Communications Officer, Irina Konstantinovsky - Executive Vice President, Chief Human Resources Officer, and Paul W. Hoelscher - Executive Vice President, Chief Financial Officer. Shao-lee Lin reports to Timothy P. Walbert, Chairman, President & CEO.